Biogen (BIIB) Change in Receivables (2009 - 2026)

Biogen's Change in Receivables history runs 18 years deep, the most recent figure standing at -$103.4 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 46.88% year-over-year to -$103.4 million; the TTM figure through Mar 2026 stood at -$135.7 million (up 46.15% YoY), while the FY2025 annual figure was -$102.7 million, up 53.8% from the prior year.
• Change in Receivables was -$103.4 million for Q1 2026 at Biogen, up from -$114.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $240.9 million in Q2 2025 to a low of -$238.2 million in Q4 2024.
• Historically, Change in Receivables has averaged -$16.8 million across 5 years, with a median of -$40.7 million in 2024.
• Biggest YoY gain for Change in Receivables was 748.24% in 2025; the steepest drop was 662.77% in 2025.
• A 5-year view of Change in Receivables shows it stood at $200.4 million in 2022, then sank by 168.76% to -$137.8 million in 2023, then plunged by 72.86% to -$238.2 million in 2024, then surged by 51.93% to -$114.5 million in 2025, then advanced by 9.69% to -$103.4 million in 2026.
• The last three Change in Receivables figures came in at -$103.4 million (Q1 2026), -$114.5 million (Q4 2025), and -$158.7 million (Q3 2025), per Business Quant data.